[Remote] Director, Value, Evidence & Outcomes Liaison (VEOL) – Central at Arcellx

Remote

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Experience in health economics and outcomes research (HEOR) and real-world evidence (RWE)
Ability to deliver and utilize clinical, value, and outcomes evidence including observational research, comparative effectiveness, and economic data
Strong communication skills to synthesize, communicate, and translate complex information into transparent, relevant, objective, and actionable insights for value-based decision makers
Experience collaborating with population-based decision makers (PHDMs) such as payers, pathway organizations, health systems, research institutions, and policy makers
Ability to establish and maintain valued relationships with PHDMs within assigned accounts at the hospital and payer level
Understanding of the access landscape, including pharmaceutical and Therapeutics (P&T) formulary inclusion, pathway development, payer medical policy coverage, and emerging competitive trends
Ability to collaborate with internal stakeholders to incorporate access insights into account planning
Knowledge of disease state, Arcellx and competitor products, health outcomes research, quality measures, healthcare policy, technology assessment, economic dynamics, and real-world evidence

Responsibilities

Deliver and utilize clinical, value, and outcomes evidence including observational research, comparative effectiveness, and economic data to address customer needs
Synthesize, communicate, and translate complex information packages and/or data into transparent, relevant, objective and actionable insights for value-based decision makers
Collaborate with PHDMs within an assigned geographic "healthcare ecosystem" to understand and address their information needs
Develop and execute the RWE/HEOR strategy collaborating with internal and field-based medical and commercial partners to deliver outstanding customer experiences
Share expertise with customers as their trusted resource on topics related to disease state, Arcellx and competitor products, health outcomes research, quality measures, healthcare policy, technology assessment, economic dynamics, and real-world evidence
Establish valued relationships with PHDMs within assigned accounts at the hospital and payer level
Build and maintain understanding of access landscape, including P&T formulary inclusion, pathway development, payer medical policy coverage, and emerging competitive trends
Collaborate with relevant internal stakeholders to incorporate access insights into account planning

Skills

Health Economic Research

Real-World Evidence

Value Research

Patient Access

Stakeholder Engagement

Policy Analysis

Arcellx

Develops immunotherapies for cell therapy

About Arcellx

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on advanced techniques that enhance the effectiveness of treatments. The company collaborates with healthcare providers and research institutions to bring these therapies to patients. Unlike many competitors, Arcellx emphasizes proprietary products and partnerships to drive their research and development efforts. The goal is to meet unmet medical needs by providing safe and effective treatment options through their innovative approach to cell therapy.

Gaithersburg, MarylandHeadquarters

2014Year Founded

$194.5MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

51-200Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Risks

Competition from established CAR-T therapies like Abecma and Carvykti could limit market share.

Dependency on Gilead's Kite partnership poses risks if partnership dynamics change.

Phase 3 iMMagine-3 trial delays or failures could impact anito-cel's market timeline.

Differentiation

Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.

The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.

ARC-SparX offers dosable and controllable CAR-T therapy options.

Upsides

Growing investment in personalized medicine aligns with Arcellx's tailored immunotherapies.

Advancements in gene editing like CRISPR enhance precision in engineered cell therapies.

Outpatient CAR-T administration could reduce costs and increase accessibility for Arcellx.

Land your dream remote job 3x faster with AI

Try Jobo Free